Premium
Investigation of screening method for DNMT3A mutations by high‐resolution melting analysis in acute myeloid leukemia
Author(s) -
Mizuta Shumpei,
Yamane Noriko,
Komai Takao,
Koba Yusuke,
Kawata Takahito,
Ukyo Naoya,
Tamekane Akira,
Watanabe Mitsumasa
Publication year - 2019
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13056
Subject(s) - high resolution melt , npm1 , myeloid leukemia , mutation , isocitrate dehydrogenase , mutation testing , biology , cancer research , point mutation , microbiology and biotechnology , genetics , gene , polymerase chain reaction , karyotype , biochemistry , chromosome , enzyme
Acute myeloid leukemia (AML) is a heterogeneous disease associated with various genetic abnormalities. Somatic mutations in nucleophosmin 1 ( NPM1 ), fms‐related tyrosine kinase 3 ( FLT3 ), and DNA methyltransferase 3 alpha ( DNMT3A ) are the most frequent mutations associated with AML. However, because DNMT3A mutations are broadly distributed, they are challenging to analyze in routine laboratory tests. Hence, we developed a rapid screening method for DNMT3A mutations by high‐resolution melting (HRM) analysis for clinical use at the point of AML diagnosis. Methods The detection limit for DNMT3A mutations from exons 8‐23 by an HRM analysis was investigated using plasmid mixtures. In 69 patients with AML, somatic mutations in NPM1 , FLT3 ‐internal tandem duplication (ITD), FLT3‐ tyrosine kinase domain (TKD), DNMT3A , and isocitrate dehydrogenase 1/2 were screened using HRM analysis, and direct sequencing was performed for positive samples. Results High‐resolution melting analysis enabled complete mutation detection in samples with 20% mutant alleles in all regions. In a clinical laboratory test, DNMT3A mutations were detected in 12 cases (17.3%), and we identified five novel mutations. Simultaneous NPM1 , FLT3 ‐ITD, and DNMT3A mutations constituted the most common pattern (30%) in de novo cytogenetically normal AML. Conclusion High‐resolution melting analysis has sufficient performance for the detection of DNMT3A mutations in AML. This approach can facilitate rapid AML genotyping at diagnosis in clinical settings.